恒旭资本3家直投企业荣获「2021年度医疗健康最具影响力企业TOP 50」_Updates_News

恒旭资本3家直投企业荣获「2021年度医疗健康最具影响力企业TOP 50」

2022-05-28

2022年5月26日，2021年度中国医疗大健康产业投融资荣耀榜通过CHC医疗传媒直播平台在线揭晓。恒旭资本投资的高诚生物、德美医疗、纳米维景荣获「2021年度医疗健康最具影响力企业TOP 50」。

「年度医疗大健康产业投融资荣耀榜」由CHC医疗咨询携手中信证券连续四届共同推出，作为第三方视角的医疗健康领域权威榜单，基于对医疗健康产业投融资发展现状的梳理，综合以机构活跃度、投资项目数、优秀案例、投资回报、管理资本总量、企业融资及发展情况、估值等多个纬度的评判标准，本着公平公正的原则，评选出了涵盖投资机构、投资人、企业、上市公司四大类，共17个奖项。

目前，恒旭资本已在医疗领域广有布局，包括爱博医疗、安智因生物、长风药业、昌郁医药、德美医疗、迪凯尔医疗、高诚生物、励楷科技、魅丽纬叶、摩漾生物、纳米维景、瑞博生物、亚虹医药、微知卓生物、UTC等多家优秀企业。恒旭资本将继续加强在医药行业的布局，不断支持国内前沿领域生物科技发展。

2021年度医疗健康最具影响力企业TOP 50.jpg

Address：5th Floor, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai

Email：scir@hengxucapital.com

Change of Address Notice

Dear investors and partners,

With your ongoing care and support, Hengxu Capital has achieved significant development and progress since its establishment. In order to better meet the needs of our business operations, our office location will be relocated to 5F, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai(Map Link: https://j.map.baidu.com/b5/x7VK).

The new office space is conveniently located with excellent facilities, providing improved conditions for meetings, receptions, and work. This relocation will facilitate better communication and collaboration between Hengxu Capital and our partners, enhancing employee satisfaction and office efficiency, and laying a solid foundation for continued and rapid business development.

The new office has been officially in use since January 29, and our mailing address has been switched to the new location. Considering the approaching Chinese New Year, we will not hold a relocation ceremony at the moment but plan to invite you to visit and guide us at a suitable time in the future.

If you have any questions or concerns, please feel free to contact us. Our phone numbers and email addresses remain unchanged. Once again, we appreciate your support and understanding, and we look forward to creating a brighter future together.

Shanghai SAIC Hengxu Capital Co., Ltd.

Jan. 29, 2024